CS-02 is under clinical development by Center Laboratories and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CS-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CS-02 overview

CS-02 is under development for the treatment of type 2 diabetes. The drug candidate is a tablet formulation administered orally. The drug candidate is a calcium channel blocker.

Center Laboratories overview

Center Laboratories subsidiary of ALK-Abello AS, is an oral solution pharmaceutical company that develops, manufactures and markets oral medical solutions. The company’s products include CNS drugs, drugs for diabetes. It provides solutions to special medication needs of infants, young children, the elderly, patients with dysphagia and special population. Center Laboratories also develops drugs for pain treatment. Center Laboratories also develop new formulations of oral solutions. The company offers clinical, regulatory, production and marketing services. It provides new drug development of specialty drugs for unmet medical needs. Center Laboratories is headquartered in Taipei, Taiwan

For a complete picture of CS-02’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.